Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 47, Issue 1, Pages 28-35Publisher
ELSEVIER
DOI: 10.1016/j.ijantimicag.2015.10.019
Keywords
Vancomycin; Infection; Continuous infusion; Intermittent infusion; Clinical efficacy; Safety
Funding
- Beijing Municipal Administration of Hospital [ZYLX201502]
Ask authors/readers for more resources
Continuous infusion of vancomycin (CIV) and intermittent infusion of vancomycin (IIV) are two major administration strategies in clinical settings. However, previous articles comparing the efficacy and safety of CIV versus IIV showed inconsistent results. Therefore, a meta-analysis was conducted to compare the efficacy and safety of CIV and IIV. PubMed, the Cochrane Library and Web of Science up to June 2015 were searched using the keywords 'vancomycin', 'intravenous', 'parenteral', 'continuous', 'intermittent', 'discontinuous', 'infusion', 'administration' and 'dosing'. Eleven studies were included in the meta-analysis. Neither heterogeneity nor publication bias were observed. Patients treated with CIV had a significantly lower incidence of nephrotoxicity compared with patients receiving IIV [risk ratio (RR) = 0.61, 95% confidence interval (CI) 0.47-0.80; P < 0.001]. No significant difference in treatment failure between the two groups was detected. Mortality between patients receiving CIV and patients receiving IIV was similar (RR = 1.15, 95% CI 0.85-1.54; P = 0.365). This meta-analysis showed that CIV had superior safety compared with IIV, whilst the clinical efficacy was not significantly different. A further multicentre, randomised controlled trial is required to confirm these results. (C) 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available